H100 CEO Eirik Grøttum purchased 407,163 shares of H100 through his associated company Kode Oslo for SEK 621,887, increasing insider holdings to over 5.3 million shares. This equity purchase is separate from H100's Bitcoin treasury, which remains at 3,506.4 BTC following a major Norwegian acquisition in August that added 2,455 BTC without cash payment. The acquisition involved issuing 790 million new shares, significantly diluting existing shareholders but increasing Bitcoin exposure. H100 is also considering future share buybacks under new Swedish rules, though no program has been announced yet. The CEO's purchase signals confidence in the company's strategy combining Bitcoin holdings with operational growth and capital market activities.
The H100 CEO's recent share purchase adds to insider holdings exceeding 5.3 million shares. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Sep 17, 2026 17:02 WIB: out of 50 priced major cryptocurrencies, 43 rose and 6 fell. Notable movers include CAKE (PancakeSwap) with a 12.10% increase and a price of Rp42.674, COTI up 11.64% at Rp325, and BAL (Balancer) rising 11.14% with a price of Rp16.297.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
